ON-013100 is a novel and potent inhibitor of cell cycle with the potential for the treatment of mantle cell lymphoma. The prodrug of ON-013100 is Briciclib (also known as ON 013105 or ON 014185) is an orally bioavailable small molecule and a disodium phosphate ester prodrug of ON 013100 with improved water solubility compared to […]

Prexasertib 2HCl (also known as LY2606368) is the dihydrochloride salt of Prexasertib with potential anticancer activity.

R547 (R-547; Ro4584820; R 547; Ro-4584820) is a potent, selective and ATP-competitive inhibitor of CDK1/2/4 with potential antitumor activity.

BML 259 is a novel and potent cyclin-dependent kinase 5 (Cdk5) inhibitor.

LDC000067 (also called LDC-000067; LDC-067) is a novel, potent, highly selective and ATP-competitive inhibitor of cyclin-dependent kinase (CDK9) with potential antineoplastic activity.

Flavopiridol HCl (also known as Alvocidib; NSC 649890; HMR-1275; L-868275; HL-275; MDL-107,826A), the HCl salt of flavopiridol which is a flavanoid, is a broad spectrum and ATP-competitive inhibitor of cyclin-dependent kinases-CDKs with potential antineoplastic activity.

LY3177833, extracted from patent US 20140275131 and patent WO 2014143601 A1 compound 4, is a novel and potent CDC7 (Cell Division Cycle 7-related Protein Kinase) and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively.

BRD6989 is an analog of the naturally occurng cortistatin A (dCA), acting as a novel, potent and selective CDK8 inhibitor with an IC50 of ~200 nM.

PHA-767491 (formerly also called CAY10572) is a novel and potent ATP-competitive dual inhibitor of Cdc7/CDK9 with IC50 of 10 nM and 34 nM in cell-free assays, respectively.

Zotiraciclib (formerly TG02, SB1317) is an orally bioavailable, brain penetrant and multi-kinase (CDK/JAK2/FLT3) inhibitor for the treatment of cancer (e.g. anaplastic astrocytoma and GBM, as well as DIPG, a rare pediatric cance).